Effect of etretinate on peripheral T lymphocytes in psoriatic patients before, during and after 6 months of therapy.
Total peripheral T lymphocytes, OKT4 helper/inducer cells and OKT8 suppressor/cytotoxic cells, as well as T lymphocyte function determined by the local xenogeneic graft-versus-host reaction (GVHR), were investigated in 14 psoriatic patients prior to institution of treatment with etretinate, during the course of treatment and 6 months after its initiation. After approximately 2 months of treatment, there was a significant increase in the number of E-rosette-forming lymphocytes and OKT4 subpopulations with a return to normal levels after 6 months of treatment. The GVHR was positive in only 5/11 patients prior to therapy but in 9/11 patients after 2 and 6 months. Our results indicate that etretinate has a stimulatory effect on T lymphocytes and their subset counts.
David
M
M
Department of Dermatology, Beilinson Medical Center, Petah Tiqva, Israel.
Shohat
B
B
Hodak
E
E
Sandbank
M
M
D000328:Adult; D000368:Aged; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D005050:Etretinate / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006087:Graft vs Host Reaction / Q000187:drug effects; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects*; D006377:T-Lymphocytes, Helper-Inducer / Q000187:drug effects; D013997:Time Factors
D005050:Etretinate